reviewTop 1% cited

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

The Lancet Oncology · 2016 · Vol. 17(8) · pp. e328–e346

Shaji Kumar✉(Mayo Clinic in Arizona)Bruno Paiva(Clinica Universidad de Navarra)Kenneth C. Anderson(Dana-Farber Cancer Institute)Brian G.M. Durie(Cedars-Sinai Medical Center)Ola Landgren(Memorial Sloan Kettering Cancer Center)Philippe MoreauNikhil C. Munshi(Dana-Farber Cancer Institute)Sagar Lonial(Emory University)Joan Bladé(Hospital Clínic de Barcelona)María‐Victoria Mateos(Instituto de Investigación Biomédica de Salamanca)Meletios Α. Dimopoulos(National and Kapodistrian University of Athens)Efstathios Kastritis(National and Kapodistrian University of Athens)Mario Boccadoro(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino)Robert Z. Orlowski(The University of Texas MD Anderson Cancer Center)Hartmut Goldschmidt(Heidelberg University)Andrew Spencer(The Alfred Hospital)Jian HouWee Joo Chng(National University Health System)Saad Z. Usmani(Levine Cancer Institute)Elena ZamagniKazuyuki Shimizu(Tokai Central Hospital)Sundar Jagannath(Tisch Cancer Institute)Hans Erik Johnsen(Aalborg University Hospital)Evangelos Terpos(National and Kapodistrian University of Athens)Tony Reiman(Dalhousie University)Robert A. Kyle(Mayo Clinic in Arizona)Pieter Sonneveld(Erasmus MC)Paul G. Richardson(Dana-Farber Cancer Institute)Philip L. McCarthy(Roswell Park Comprehensive Cancer Center)Heinz Ludwig(Wilhelminen Hospital)Wen-Ming Chen(Beijing Chaoyang Emergency Medical Center)Michèle CavoJean‐Luc HarousseauSuzanne Lentzsch(Columbia University)Jens Hillengaß(Heidelberg University)Antonio Palumbo(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino)Alberto Órfão(Instituto de Investigación Biomédica de Salamanca)S. Vincent Rajkumar(Mayo Clinic in Arizona)Jesús F. San Miguel(Clinica Universidad de Navarra)Hervé Avet‐Loiseau(Université de Toulouse)

View via DOI Publisher page

Multiple Myeloma Research and Treatments Protein Degradation and Inhibitors Peptidase Inhibition and AnalysisMultiple myelomaMinimal residual diseaseMedicineBone marrowMyeloma proteinClinical trialDiseaseOncologyMonoclonalInternal medicine